← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › H2-receptor antagonists
lafutidine
A02BA08
Adult Dosing
- Gastric ulcer: 10 mg orally twice daily (morning and evening)
- Gastritis, GERD, and mucosal lesions: 10 mg orally twice daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Gastric ulcer
- Gastritis
- Gastroesophageal reflux disease (GERD)
- Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) in acute gastritis and acute exacerbation of chronic gastritis
Mechanism of Action
- Competitive histamine H2-receptor antagonist
- Inhibits basal and stimulated gastric acid secretion
- Enhances gastric mucosal defense mechanisms via stimulation of capsaicin-sensitive sensory nerves and endogenous calcitonin gene-related peptide (CGRP) release
Contraindications
- Hypersensitivity to lafutidine or other H2-receptor antagonists
Adverse Reactions
- Constipation
- Diarrhea
- Dizziness
- Headache
- Rash
- Elevated liver enzymes (AST, ALT)
Drug Interactions
- Drugs dependent on gastric pH for absorption (e.g., ketoconazole, itraconazole) may have decreased absorption
- No clinically significant cytochrome P450 enzyme inhibition or induction reported at standard doses
Curated Content: Needs Vetting Before Put to Clinical Use